Sun Pharma Advanced Research Company Limited (SPARC) has released its unaudited consolidated financial results for the quarter and half-year ended September 30, 2024, reflecting a challenging period with a decline in revenue and an increase in losses.
For Q2 FY2024, SPARC reported revenue from operations of ₹12.86 crore, down significantly from ₹21.18 crore in the same quarter last year. This marks a sharp decline, signaling a slowdown in the company’s operational performance.
The company’s net loss for the quarter widened to ₹107.33 crore, compared to a loss of ₹86.42 crore in Q2 FY2023. The increased loss reflects higher expenses or reduced revenue streams, impacting the company’s profitability.
For the half-year ending September 30, 2024, SPARC reported total revenue of ₹29.67 crore, compared to ₹45.13 crore in the corresponding period last year. The net loss for the half-year period was ₹201.77 crore, compared to a loss of ₹181.77 crore in H1 FY2023, indicating ongoing financial challenges.
